ALX Oncology Holdings Inc. (ALXO)

1.9100 -0.0800 (-4.02%) At close: 04:00PM EDT

ALX Oncology Holdings Inc.

323 Allerton Avenue
South San Francisco, CA 94080
United States
650 466 7125
https://www.alxoncology.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 81

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Corey S. Goodman Ph.D.	Executive Chairman	90.39k	N/A	1952
Mr. Jason W. Lettmann	CEO & Director	834.32k	N/A	1977
Dr. Jaume Pons Ph.D.	Founder, President, Chief Scientific Officer & Director	1.01M	N/A	1966
Mr. Peter S. Garcia M.B.A.	Chief Financial Officer	679.66k	N/A	1962
Dr. Sophia Randolph M.D., Ph.D.	Chief Medical Officer & Director	714k	N/A	1968
Dr. Michael Chang Ph.D.	Vice President of Operations	N/A	N/A	N/A
Ms. Shelly Pinto	Senior VP of Finance & Chief Accounting Officer	508.26k	N/A	1977
Caitlyn Doherty	Manager of Investor Relations & Corporate Communications	N/A	N/A	N/A
Dr. Christopher Byrd J.D., Ph.D.	General Counsel	N/A	N/A	N/A
Dr. Athanasios Tsiatis M.D.	Senior Vice President of Clinical Development	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Corporate Governance

ALX Oncology Holdings Inc.’s ISS Governance QualityScore as of September 1, 2024 is 8. The pillar scores are Audit: 7; Board: 6; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.